Moderna Inc Market Cap ($54.14 Billion)
Market Cap & Net Worth: Moderna Inc (MRNA)
Moderna Inc market cap. Moderna Inc (NASDAQ:MRNA) has a market capitalization of $54.14 Billion ($54.14 Billion) as of November 1, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #495 globally and #251 in its home market, demonstrating a 9.42% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Moderna Inc's stock price $221.72 by its total outstanding shares 399235889 (399.24 Million). Also see how efficiently does Moderna Inc generate cash for how efficiently the company converts equity into cash flow.
Moderna Inc Market Cap History (2018–2026)
Moderna Inc market cap history from 2018 to 2026. Data shows growth from $6.10 Billion to $88.52 Billion (36.84% CAGR). Check MRNA share price today for real-time trading data and today's change.
Index Memberships
Moderna Inc is a constituent of 5 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
ARCA Biotechnology
BTK
|
$1.06 Trillion | 5.13% | #6 of 30 |
|
S&P 500 Index
GSPC
|
$61.47 Trillion | 0.02% | #198 of 503 |
|
NASDAQ Health Care
IXHC
|
$2.62 Trillion | 2.07% | #8 of 976 |
|
NASDAQ Composite
IXIC
|
$40.09 Trillion | 0.14% | #75 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.84 Trillion | 2.94% | #6 of 263 |
Weight: Moderna Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Moderna Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Moderna Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore Moderna Inc (MRNA) net asset momentum to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
6.06x
Moderna Inc's market cap is 6.06 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2018 | $6.10 Billion | $122.51 Million | -$384.73 Million | 49.76x | N/A |
| 2019 | $7.81 Billion | $48.04 Million | -$514.02 Million | 162.57x | N/A |
| 2020 | $41.71 Billion | $274.49 Million | -$747.06 Million | 151.95x | N/A |
| 2021 | $101.40 Billion | $17.74 Billion | $12.20 Billion | 5.72x | 8.31x |
| 2022 | $71.71 Billion | $18.88 Billion | $8.36 Billion | 3.80x | 8.58x |
| 2023 | $39.70 Billion | $6.85 Billion | -$4.71 Billion | 5.80x | N/A |
| 2024 | $16.60 Billion | $3.20 Billion | -$3.56 Billion | 5.19x | N/A |
| 2025 | $11.77 Billion | $1.94 Billion | -$2.82 Billion | 6.06x | N/A |
Competitor Companies of MRNA by Market Capitalization
Companies near Moderna Inc in the global market cap rankings as of November 1, 2026. Also see total assets of Moderna Inc for a full breakdown of the balance sheet.
Key companies related to Moderna Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #182 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #371 globally with a market cap of $76.14 Billion USD.
- Argen-X (BR:ARGX): Ranked #562 globally with a market cap of $47.46 Billion USD ( €40.60 Billion EUR).
- Samsung Biologics Co Ltd (KO:207940): Ranked #574 globally with a market cap of $46.65 Billion USD ( ₩68.83 Trillion KRW).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #182 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $558.88 |
| #371 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $927.89 |
| #562 | Argen-X | BR:ARGX | $47.46 Billion | €807.20 |
| #574 | Samsung Biologics Co Ltd | KO:207940 | $46.65 Billion | ₩1487000.00 |
Market Capitalization of Moderna Inc (2018–2026)
Market capitalization of Moderna Inc from 2018 to today. Between 2018 and today, Moderna Inc's market cap moved from $6.10 Billion to $ 88.52 Billion, with a yearly change of 36.84%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $88.52 Billion | +651.85% |
| 2025 | $11.77 Billion | -29.08% |
| 2024 | $16.60 Billion | -58.19% |
| 2023 | $39.70 Billion | -44.63% |
| 2022 | $71.71 Billion | -29.28% |
| 2021 | $101.40 Billion | +143.11% |
| 2020 | $41.71 Billion | +434.10% |
| 2019 | $7.81 Billion | +28.09% |
| 2018 | $6.10 Billion | -- |
End of Day Market Cap According to Different Sources
On Oct 31st, 2026 the market cap of Moderna Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $54.14 Billion USD |
| MoneyControl | $54.14 Billion USD |
| MarketWatch | $54.14 Billion USD |
| marketcap.company | $54.14 Billion USD |
| Reuters | $54.14 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Moderna Inc
Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company's respiratory vaccines include spikevax, mNEXSPIKE, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, and human immunodeficiency virus vaccines; enteric viruses incl… Read more